BRAF and melanoma: While activating mutations in the RAS gene family have long been accepted as early events in this process [16], mutations in the B-RAF gene have only recently been recognized for their important contribution to tumor progression Primary malignant melanomas harbor B-RAF mutations at a frequency of 60–67%, while colorectal cancers are affected in approximately 10–12% of all cases sampled.